Disparities in the time it takes for patients to access new medicines in different EU Member States are increasing.
Published today, the most comprehensive EFPIA WAIT Indicator Survey to date found that the average time to reimbursement for innovative treatments across EU and European Economic Area (EEA) countries continues to be as long as 511 days. Patients in Germany wait around 133 days to access new medicines compared to patients in Romania that endure a wait of more than 899 days.
A new initiative will make available previously unpublished data on chemicals tested to develop medicines.
Read more
World Health Day
Rising temperatures and sea levels, increasing CO2 levels, extreme weather affect people’s health. Find out more about what the pharmaceutical industry is doing to tackle climate change and build a #HealthierTomorrow
The continent is eager to capitalise on BioNTech’s Covid-19 success — but matching the scale of US hubs will be hard...
Read more
About the EFPIA newsletter
The European Federation of Pharmaceutical Industries and Associations (EFPIA) represents the pharmaceutical industry operating in Europe. Through its direct membership of 37 national associations and 40 leading pharmaceutical companies, EFPIA is the voice on the EU scene of 1,900 companies committed to researching, developing and bringing to patients new medicines that will improve health and the quality of life around the world.